Azita Saleki-Gerhardt
Known title: DirectorCIK: 0001563545
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.
Transaction History
| ENTG | ▲ Buy | Grant | 1,412 | $0 | 5/6/2026 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 16,309 | $3.8M | 2/27/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 6,058 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 7,074 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 6,638 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Grant | 17,041 | $0 | 2/18/2026 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 42,370 | $2.3M | 8/12/2025 | View on chart |
| ABBV | ▼ Sell | Open Market | 42,370 | $8.4M | 8/12/2025 | View on chart |
| ENTG | ▲ Buy | Grant | 2,897 | $0 | 4/23/2025 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 17,056 | $3.5M | 2/28/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 17,986 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 6,060 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 7,074 | $0 | 2/13/2025 | View on chart |
| ABBV | ▲ Buy | Grant | 7,378 | $0 | 2/13/2025 | View on chart |
| ABBV | ▼ Sell | Gift | 25,630 | $0 | 9/24/2024 | View on chart |
| ENTG | ▲ Buy | Grant | 1,643 | $0 | 4/24/2024 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 23,966 | $4.3M | 2/28/2024 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 52,870 | $3.1M | 2/21/2024 | View on chart |
| ABBV | ▼ Sell | Open Market | 52,870 | $9.2M | 2/21/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 8,558 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 32,097 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 7,380 | $0 | 2/15/2024 | View on chart |
| ABBV | ▲ Buy | Grant | 6,060 | $0 | 2/15/2024 | View on chart |
| ENTG | ▲ Buy | Grant | 2,849 | $0 | 4/26/2023 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 26,990 | $1.4M | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 780 | $120K | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 9,220 | $1.4M | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 26,990 | $4.2M | 3/1/2023 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 33,359 | $5.1M | 2/28/2023 | View on chart |
| ABBV | ▲ Buy | Option Exercise | 25,000 | $1.3M | 2/17/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 14,246 | $2.1M | 2/17/2023 | View on chart |
| ABBV | ▼ Sell | Open Market | 10,754 | $1.6M | 2/17/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 11,229 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 8,560 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 7,380 | $0 | 2/16/2023 | View on chart |
| ABBV | ▲ Buy | Grant | 48,127 | $0 | 2/16/2023 | View on chart |
| ENTG | ▲ Buy | Grant | 1,849 | $0 | 4/27/2022 | View on chart |
| ABBV | ▼ Sell | Tax Withholding | 22,108 | $3.3M | 2/25/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 25,612 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 5,568 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 11,229 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 7,490 | $0 | 2/17/2022 | View on chart |
| ABBV | ▲ Buy | Grant | 13,837 | $0 | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Entegris Shares Gain After Analysts Adopt More Constructive View
Analysts have shifted to a more positive outlook on Entegris, lifting its fair‑value estimate modestly. The stock, however, fell along with other semiconductor names such as Micron and AMD, reflecting broader sector weakness. The lift comes amid a broader rebound in the semiconductor sector after a recent dip, but the price remains below the 200‑day moving average.
Entegris Shares Gain After Analysts Adopt More Constructive View. Analysts have shifted to a more positive outlook on Entegris, lifting its fair‑value estimate modestly. The stock, however, fell along with other semiconductor names such as Micron and AMD, reflecting broader sector weakness. The lift comes amid a broader rebound in the semiconductor sector after a recent dip, but the price remains below the 200‑day moving average.